Latest news with #ZAVA
Scottish Sun
13-06-2025
- Health
- Scottish Sun
The truth about why weight loss jabs are failing to work for thousands of Brits
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) WEIGHT loss jabs have been a godsend for people in the UK living with obesity. But despite 1.5 million people using the weight loss medication in a single month, many users say they haven't seen the expected results from GLP-1 treatments. Sign up for Scottish Sun newsletter Sign up 3 While weight loss plateaus are common, there are reasons weight loss jabs may not be working, with fixable solutions Credit: Getty Weight loss plateaus are common, but in many cases, the reasons are identifiable and fixable. To help those facing this challenge, experts at ZAVA have broken down the most common reasons the weight loss injection Mounjaro may not be working as expected - and what you can do to get back on track. 1. Incorrect medicine Mounjaro's effectiveness often increases as you move up the dosage ladder. The medication is introduced to the body slowly (titration) to reduce side effects, eventually reaching maintenance doses of up to 15mg per week. If you're still on a lower dose or haven't advanced as recommended, your weight loss may be limited. Consistency is crucial. Skipping doses, delaying titration, or not following your provider's schedule can reduce the medication's impact. Many people don't feel the full effect until eight to 12 weeks in, so patience and adherence are key. You should give Mounjaro at least three months before judging its effectiveness. If you're experiencing side effects, it's absolutely fine to remain at a lower dose for longer. The experts advise stepping up more slowly if you're not tolerating side effects well - there's no need to push through discomfort. Women taking fat jabs need 'effective contraception' - as health chiefs warn of serious harm to unborn babies You can always increase the dose later once your body has adjusted. Comfort and tolerability are just as important as consistency for long-term success. Poor diet and lack of exercise While Mounjaro helps reduce appetite, it doesn't override the fundamental rule of weight loss: you must burn more calories than you consume. Even with a smaller appetite, eating more than your body needs will still cause progress to stall. To maintain an effective calorie deficit for weight loss, men are generally advised to consume around 1,900 calories per day (down from the typical 2,500), while women should aim for about 1,400 calories per day (down from around 2,000). Healthy diet tips: Be strict with calorie tracking until portion control becomes second nature Aim for a 600-calorie daily deficit to lose weight steadily Prioritise whole foods over high-sugar, high-fat processed options Follow a diet plan tailored to your needs, and explore healthy recipe ideas to stay on track The experts say to also remember that initial weight loss may come from water, especially if you've reduced salt or started exercising. As your body adjusts, weight loss may temporarily plateau or appear to reverse. Finally, stay hydrated and limit alcohol. Alcohol can interfere with your metabolism and reduce the effectiveness of Mounjaro. 3. Stress and sleep issues 3 Not getting enough sleep could act as a major weight loss blocker Credit: Getty Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move. You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, the experts say to prioritise stress management techniques (like mindfulness or journaling), and aim for seven to nine hours of sleep per night. 4. Health conditions and medications Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss. If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. The experts advise regular follow-up helps ensure your treatment plan remains safe and effective. 5. Unrealistic expectations 3 It's important to remember weight is a long-term process Credit: Getty It's natural to hope for rapid results, especially with a promising medication like Mounjaro. But weight loss is a long-term process. Initial drops (often water weight) can be misleading. Progress will slow, and that's okay. Avoid comparing yourself to others or obsessively checking the scale, say the experts. Focus on consistency, not speed. Your journey is unique, and sustainable weight loss takes time. 6. Lack of support Motivation by itself often isn't enough. Without support from those who understand your goals, the journey can feel lonely and overwhelming. The experts recommend: Lean on friends and family who encourage you Join online communities or local support groups, including NHS-recommended programs Consider working with a dietitian or coach for personalised guidance and accountability How to boost weight loss on Mounjaro, according to a doctor Dr Crystal Wyllie, a qualified and UK registered doctor who is part of the clinical team at Asda Online Doctor by ZAVA, says while Mounjaro is an effective medication for weight loss, it's normal to encounter a plateau at some point. She advises: "To enhance your results, it's important to follow the prescribed dosing schedule and aim to reach the appropriate maintenance dose, as higher doses are generally associated with greater benefits. "However, if you're experiencing side effects, it's perfectly acceptable to step up more slowly. "Your GP may recommend staying on a lower dose for longer until your body adjusts, comfort and tolerability should always guide the pace of titration." Beyond medication, factors like maintaining a balanced diet, regular physical activity, managing stress, and getting enough sleep play a vital role in supporting your weight loss journey, says Dr Wyllie. She adds: "If progress stalls despite these efforts, consulting your healthcare provider is essential to evaluate your plan and make necessary adjustments." For individuals who find Mounjaro less effective or unsuitable, there are several other weight loss medications to consider. Dr Wyllie recommends: "Injectable options like Wegovy and Nevolat work similarly by curbing appetite, while oral medications such as Orlistat, Xenical, and the over-the-counter Alli provide different mechanisms to support weight loss. "Each treatment has unique advantages and considerations, so working closely with your doctor ensures you receive the safest and most personalised approach to achieve your goals.' Before beginning any weight loss treatment, please consult your GP or healthcare professional. These treatments may not be suitable for everyone.
The Sun
13-06-2025
- Health
- The Sun
The truth about why weight loss jabs are failing to work for thousands of Brits
WEIGHT loss jabs have been a godsend for people in the UK living with obesity. But despite 1.5 million people using the weight loss medication in a single month, many users say they haven't seen the expected results from GLP-1 treatments. 3 Weight loss plateaus are common, but in many cases, the reasons are identifiable and fixable. To help those facing this challenge, experts at ZAVA have broken down the most common reasons the weight loss injection Mounjaro may not be working as expected - and what you can do to get back on track. 1. Incorrect medicine Mounjaro's effectiveness often increases as you move up the dosage ladder. The medication is introduced to the body slowly (titration) to reduce side effects, eventually reaching maintenance doses of up to 15mg per week. If you're still on a lower dose or haven't advanced as recommended, your weight loss may be limited. Consistency is crucial. Skipping doses, delaying titration, or not following your provider's schedule can reduce the medication's impact. Many people don't feel the full effect until eight to 12 weeks in, so patience and adherence are key. You should give Mounjaro at least three months before judging its effectiveness. If you're experiencing side effects, it's absolutely fine to remain at a lower dose for longer. The experts advise stepping up more slowly if you're not tolerating side effects well - there's no need to push through discomfort. Women taking fat jabs need 'effective contraception' - as health chiefs warn of serious harm to unborn babies You can always increase the dose later once your body has adjusted. Comfort and tolerability are just as important as consistency for long-term success. Poor diet and lack of exercise While Mounjaro helps reduce appetite, it doesn't override the fundamental rule of weight loss: you must burn more calories than you consume. Even with a smaller appetite, eating more than your body needs will still cause progress to stall. To maintain an effective calorie deficit for weight loss, men are generally advised to consume around 1,900 calories per day (down from the typical 2,500), while women should aim for about 1,400 calories per day (down from around 2,000). Healthy diet tips: Be strict with calorie tracking until portion control becomes second nature Aim for a 600-calorie daily deficit to lose weight steadily Prioritise whole foods over high-sugar, high-fat processed options Follow a diet plan tailored to your needs, and explore healthy recipe ideas to stay on track The experts say to also remember that initial weight loss may come from water, especially if you've reduced salt or started exercising. As your body adjusts, weight loss may temporarily plateau or appear to reverse. Finally, stay hydrated and limit alcohol. Alcohol can interfere with your metabolism and reduce the effectiveness of Mounjaro. 3. Stress and sleep issues 3 Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move. You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, the experts say to prioritise stress management techniques (like mindfulness or journaling), and aim for seven to nine hours of sleep per night. 4. Health conditions and medications Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss. If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. The experts advise regular follow-up helps ensure your treatment plan remains safe and effective. 5. Unrealistic expectations 3 It's natural to hope for rapid results, especially with a promising medication like Mounjaro. But weight loss is a long-term process. Initial drops (often water weight) can be misleading. Progress will slow, and that's okay. Avoid comparing yourself to others or obsessively checking the scale, say the experts. Focus on consistency, not speed. Your journey is unique, and sustainable weight loss takes time. 6. Lack of support Motivation by itself often isn't enough. Without support from those who understand your goals, the journey can feel lonely and overwhelming. The experts recommend: Lean on friends and family who encourage you Join online communities or local support groups, including NHS-recommended programs Consider working with a dietitian or coach for personalised guidance and accountability How to boost weight loss on Mounjaro, according to a doctor Dr Crystal Wyllie, a qualified and UK registered doctor who is part of the clinical team at Asda Online Doctor by ZAVA, says while Mounjaro is an effective medication for weight loss, it's normal to encounter a plateau at some point. She advises: "To enhance your results, it's important to follow the prescribed dosing schedule and aim to reach the appropriate maintenance dose, as higher doses are generally associated with greater benefits. "However, if you're experiencing side effects, it's perfectly acceptable to step up more slowly. "Your GP may recommend staying on a lower dose for longer until your body adjusts, comfort and tolerability should always guide the pace of titration." Beyond medication, factors like maintaining a balanced diet, regular physical activity, managing stress, and getting enough sleep play a vital role in supporting your weight loss journey, says Dr Wyllie. She adds: "If progress stalls despite these efforts, consulting your healthcare provider is essential to evaluate your plan and make necessary adjustments." For individuals who find Mounjaro less effective or unsuitable, there are several other weight loss medications to consider. Dr Wyllie recommends: "Injectable options like Wegovy and Nevolat work similarly by curbing appetite, while oral medications such as Orlistat, Xenical, and the over-the-counter Alli provide different mechanisms to support weight loss. "Each treatment has unique advantages and considerations, so working closely with your doctor ensures you receive the safest and most personalised approach to achieve your goals.' Before beginning any weight loss treatment, please consult your GP or healthcare professional. These treatments may not be suitable for everyone.
Yahoo
04-06-2025
- Business
- Yahoo
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
Hims & Hers Health, Inc. HIMS announced its agreement to acquire ZAVA, a digital health platform in Europe. The deal, which marks a significant step toward its global expansion, will likely expand HIMS' footprint in the U.K. and will officially launch the company into Germany, France and Ireland, with more markets anticipated soon. The acquisition is expected to close in the second half of 2025, and the deal is expected to be accretive by 2026. Hims & Hers is also planning to introduce a new, personalized dimension of digital health in Europe. Through this, the company aims to provide individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health. To ensure a localized experience, this expansion is also expected to include access to British, German and French healthcare providers in local languages. Hims & Hers expects to share more about the offerings and their rollout in the coming months. The latest acquisition and subsequent expansion in the European markets are expected to significantly solidify HIMS' international footprint. Following the announcement, shares of the company lost nearly 3.6% till yesterday's closing. Historically, the company has gained synergies from its various strategic buyouts. Although the latest deal is likely to be beneficial for HIMS' top-line growth going forward, the stock declined overall. Hims & Hers currently has a market capitalization of $12.25 billion. It has an earnings yield of 1.3%, favorable than the industry's negative yield. In the last reported quarter, HIMS delivered an earnings surprise of 66.7%. Hims & Hers aims to establish its own branded presence, leveraging the ZAVA platform in each of the European markets in the coming quarters and strengthening its digital health offerings on a global scale. It is worth mentioning that ZAVA, which currently serves more than 1.3 million active customers, has an in-house medical team that delivered nearly 2.3 million consultations in 2024 across the U.K., Germany, France and Ireland. Hims & Hers' management expects to leverage ZAVA's established European presence to transform access to care for people across Europe battling widespread, often silent chronic conditions like obesity and depression. Per a report by Grand View Research, the global digital health market was estimated at $288.55 billion in 2024 and is anticipated to witness a CAGR of 22.2% between 2025 and 2030. Factors like the rising incidence of chronic conditions fueling the demand for remote monitoring and management solutions, and technological advancements are likely to drive the market. Given the market potential, the latest buyout is expected to be a significant milestone for Hims & Hers and boost its business globally. In February, Hims & Hers acquired a U.S.-based peptide facility based in California. The buyout will likely enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment options. The same month, Hims & Hers acquired an at-home lab testing facility, Sigmund NJ LLC, which is marketed as Trybe Labs. The buyout will likely enable HIMS to support at-home blood draws and more comprehensive whole-body testing. The acquisition is also expected to broaden the company's ability to offer a wide range of personalized treatments, supplements and medications and accelerate the expansion into new clinical categories, including low testosterone, perimenopausal and menopausal support. Shares of the company have surged 154.1% in the past year compared with the industry's 33.8% rise and the S&P 500's gain of 11.4%. Image Source: Zacks Investment Research Currently, HIMS carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are HealthEquity, Inc. HQY, Cencora, Inc. COR and Integer Holdings Corporation ITGR. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 20.3%. HQY's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 12.4%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. HealthEquity's shares have gained 34.9% against the industry's 21.7% decline in the past year. Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Cencora has rallied 25.3% against the industry's 21.7% decline in the past year. Integer Holdings, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Integer Holdings' shares have lost 0.7% compared with the industry's 13.2% plunge in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Business
- Yahoo
Hims & Hers Expands in Europe With Acquisition of ZAVA
Hims & Hers expanding in Europe with the purchase of London-based digital health platform ZAVA. The acquisition gives the health and wellness site an increased reach in the U.K., and launches the firm in Germany, France, and Ireland. The price of the all-cash deal was not & Hers Health (HIMS) shares rose Tuesday after the health and wellness site announced it was expanding its reach into Europe by buying London-based digital health platform ZAVA. The price of the all-cash deal was not disclosed. Hims & Hers explained that the purchase will increase its presence in the U.K., and give the firm an entry into Germany, France, and Ireland, "with more markets anticipated soon." Founder and CEO Andrew Dudum said by leveraging ZAVA's "established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe." The company added that it would soon introduce "a new, personalized dimension of digital health in Europe, providing individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health." Hims & Hers noted that the acquisition would be paid for from the company's balance sheet, and is expected to close in the second half of this year. It expects the addition of ZAVA to be accretive by next year. Shares of Hims & Hers advanced about 3% in recent trading and have soared about 130% this year. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
03-06-2025
- Business
- Business Wire
Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acquire ZAVA, a leading digital health platform in Europe. This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. This acquisition is expected to accelerate Hims & Hers' vision to deliver the same seamless, personalized care experience it has successfully built in the U.S. to millions more people globally. Hims & Hers will establish its own branded presence, leveraging the robust ZAVA platform, in each of these European markets in the coming quarters. By combining ZAVA's trusted European operations, medical rigor, and seamless digital experience with Hims & Hers' proven, trusted brand, the company is poised to become a leader in digital health globally, delivering access to personalized care that meets people where they are. This strategic acquisition will significantly strengthen Hims & Hers' international footprint. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France, and Ireland. Hims & Hers will soon introduce a new, personalized dimension of digital health in Europe, providing individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health. To ensure a world-class and localized experience, this expansion will include access to British, German, and French healthcare providers in local languages. While Hims & Hers will share more about the offerings and their rollout in the coming months, they expect the deal to be accretive by 2026. 'The demand for simpler, more personalized healthcare is universal,' said Andrew Dudum, founder and CEO of Hims & Hers. 'By leveraging ZAVA's established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe. Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve.' 'Wherever you live, the need is the same: healthcare that's personal, trustworthy and fast. By joining forces with Hims & Hers, we can put that standard within reach of millions more people across Europe,' said David Meinertz, co-founder and CEO of ZAVA. 'Together we'll pair ZAVA's trusted clinical services, established footprint, and deep understanding of the European healthcare landscape with the Hims & Hers experience to make affordable access to high-quality, personalized care the rule, not the exception. I'm thrilled to be working with Andrew and his team. It's still day one for digital healthcare, and I can't wait to see what we'll achieve for patients in the years ahead.' The acquisition consideration will be comprised of 100% cash, to be funded from the company's balance sheet at closing. The acquisition is expected to close in the second half of 2025, and Hims & Hers expects to continue expanding globally as demand for personalized healthcare continues to grow. For more information, please see About Hims & Hers Health, Inc Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit and About ZAVA ZAVA is a leading digital health platform in Europe, on a mission to make high-quality, dependable healthcare accessible and affordable. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France and Ireland - putting compassionate, clinically-robust healthcare in people's hands 24/7. Rated 'outstanding' for leadership by the UK Care Quality Commission, ZAVA combines medical rigour with a friction-free digital experience. ZAVA's comprehensive service portfolio spans weight management, women's and men's health, sexual health, general medicine and skin & hair care - helping people tackle both everyday and sensitive conditions quickly, discreetly and safely. Cautionary Note Regarding Forward-Looking Statements Except for historical information, certain statements in this press release, including statements regarding the timing and effects of entering into the acquisition described above, our future performance, anticipated customer demand, the ability to scale our business, the solutions accessible on our platform, and the underlying assumptions with respect to the foregoing, are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions, our legal and regulatory environment, macroeconomic and geopolitical factors, and those factors described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the 'Commission'). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.
